News | June 16, 2015

Molecular MRI Aims at Component of Multiple Cancers

Novel MRI agents successfully target tumor-specific physiology

molecular MRI, contrast agents, PSMA, cancer, SNMMI, Sangeeta Ray

June 16, 2015 - The prostate-specific membrane antigen (PSMA) biomarker is the bullseye for three new magnetic resonance imaging (MRI) agents that bind to the protein in not only prostate cancer, but a range of tumor types. The agents were discussed in research unveiled at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

'We have shown in this proof-of-concept study that PSMA could serve as a biomarker for MR-based molecular imaging due to its high concentration within target cells, limited expression within non-targeted tissues and accessibility on the cell surface,' said Sangeeta Ray, Ph.D., principal investigator for the study and assistant professor in the Russell H. Morgan Department of Radiology and Radiological Science at the Johns Hopkins Medical Institutions in Baltimore, Maryland.

PSMA is found in both primary and metastatic prostate tumors, and within newly developing blood vessels of many non-prostate cancers. An investigational imaging agent, if approved, could one day contribute to patient management by helping clinicians direct biopsies and cancer therapies.

In this study, PSMA binding affinities were assessed for three MR contrast agents, which were then imaged in living cells using a 9.4 Tesla magnet MR system. Results of the study showed the three synthesized gadolinium-based contrast agents (Gd-1, Gd-2, and Gd-3) were able to assess parameters of PSMA in the experimental cell lines and mouse models of prostate cancer. Gd-3 demonstrated the most MR contrast enhancement, about 36 percent, and demonstrated PSMA-mediated uptake on MR images of mice.

As encouraging as the research is, these agents are still in preliminary stages of study and will need to be investigated further.

'With adequate funding, we estimate that a lead compound could be tested in human patients within the next two to three years,' said Ray.

For more information: www.snmmi.org

Related Content

Chest X-ray AI Algorithm Correctly Identifies Lung Disease for Dubai Health Authority
Feature | Artificial Intelligence | April 17, 2018
The Dubai Health Authority (DHA) announced the preliminary results of a chest X-ray artificial intelligence (AI)...
First Patient Treated in Online Adaptive Radiotherapy Trial With CyberKnife System
News | Stereotactic Body Radiation Therapy (SBRT) | April 06, 2018
Accuray Inc. and Erasmus MC announced the first patient has been successfully treated using an online-adaptive (OA)...
News | Endoscopes | April 02, 2018
Results from a recent prospective trial found the Wide Area Transepithelial Sampling with 3D Tissue Analysis (WATS3D)...
Edwards Completes Enrollment in PARTNER 3 Low-Risk CT Sub-Study
News | Computed Tomography (CT) | March 27, 2018
March 27, 2018 — Edwards Lifesciences Corp.
Combination Radiotherapy Beneficial in Treating Prostate Cancer
News | Prostate Cancer | March 27, 2018
March 27, 2018 — While there are many treatment options for men with...
3-D Printed Models Improve Medical Student Training
News | Medical 3-D Printing | March 23, 2018
March 23, 2018 — A relatively inexpensive...
What is the cost of interrupting a radiologist?
News | Clinical Study | March 20, 2018
March 20, 2018 – A first of its kind study...
Overlay Init